-- After three years, 74 percent (174/234) of patients achieved ASAS20.
-- After three years, 42 percent (97/234) of patients achieved ASAS
Physicians measure the severity of AS on a scale of 0-100 for level of
pain, function, inflammation and a general overall assessment by the
patient. Partial remission of the disease is classified as a score of less
than 20 on a 0-100 scale in each of those four assessments.
-- The most common adverse experiences occurring in greater than or equal
to five percent of patients during three years of exposure were
nasopharyngitis, upper respiratory tract infection and headache.
-- There were no cases of tuberculosis or demyelinating disorders. There
was one death caused by malignancy.
About Ankylosing Spondylitis (AS)
AS is a rheumatic condition that affects young adults, and is more common in men than in women. Ankylosis means "fusion" and spondylitis means "inflammation of the spine." Advanced AS can lead to new bone formation on the spine causing it to fuse in a fixed position. It commonly begins before the age of 35. It is estimated that nearly three million people in Europe and at least half a million people in the United States are affected by AS or a related spondyloarthropathy. However, there are likely more people affected by AS because it is under-recognized and under-diagnosed.
Important Safety Information
Globally, prescribing information varies; refer to the individual country product label for complete information.
Serious infections, sepsis, rare cases of tuberculosis (TB), and
opportunistic infections, including fatalities, have been reported with the
use of TNF antagonists, including HUMIRA. Many of the serious infections
have occurred in patients on concomitant immunosuppressive therapy that,
Copyright©2008 PR Newswire.
All rights reserved